US6419931B1
(en)
*
|
1991-08-26 |
2002-07-16 |
Epimmune Inc. |
Compositions and methods for eliciting CTL immunity
|
US20030152580A1
(en)
*
|
1994-07-21 |
2003-08-14 |
Alessandro Sette |
Hla binding peptides and their uses
|
US7611713B2
(en)
*
|
1993-03-05 |
2009-11-03 |
Pharmexa Inc. |
Inducing cellular immune responses to hepatitis B virus using peptide compositions
|
US7252829B1
(en)
*
|
1998-06-17 |
2007-08-07 |
Idm Pharma, Inc. |
HLA binding peptides and their uses
|
US20110097352A9
(en)
*
|
1992-01-29 |
2011-04-28 |
Pharmexa Inc. |
Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
|
IL105554A
(en)
*
|
1992-05-05 |
1999-08-17 |
Univ Leiden |
Peptides of human papillomavirus for use in preparations elicit a human T cell response
|
US9340577B2
(en)
*
|
1992-08-07 |
2016-05-17 |
Epimmune Inc. |
HLA binding motifs and peptides and their uses
|
US9266930B1
(en)
*
|
1993-03-05 |
2016-02-23 |
Epimmune Inc. |
Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
|
US6540994B1
(en)
*
|
1997-07-18 |
2003-04-01 |
I.D.M. Immuno-Designed Molecules |
Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
|
US6410022B1
(en)
*
|
1995-05-01 |
2002-06-25 |
Avant Immunotherapeutics, Inc. |
Modulation of cholesteryl ester transfer protein (CETP) activity
|
US5853719A
(en)
*
|
1996-04-30 |
1998-12-29 |
Duke University |
Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
|
US7888100B2
(en)
*
|
1996-10-03 |
2011-02-15 |
Memorial Sloan-Kettering Cancer Research |
Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
|
US6465251B1
(en)
*
|
1996-11-13 |
2002-10-15 |
Dana-Farber Cancer Institute, Inc. |
Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin
|
US6087441A
(en)
*
|
1997-02-05 |
2000-07-11 |
Ludwig Institute For Cancer Research |
Structurally modified peptides that are resistant to peptidase degradation
|
WO1998058951A1
(fr)
*
|
1997-06-23 |
1998-12-30 |
Ludwig Institute For Cancer Research |
Nonapeptides et decapeptides isoles se fixant a des molecules hla, et leur utilisation
|
US6548296B1
(en)
|
1997-07-23 |
2003-04-15 |
Roche Diagnostics Gmbh |
Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
|
US5891432A
(en)
*
|
1997-07-29 |
1999-04-06 |
The Immune Response Corporation |
Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
|
US5965535A
(en)
*
|
1997-09-12 |
1999-10-12 |
Ludwig Institute For Cancer Research |
Mage-3 peptides presented by HLA class II molecules
|
CA2316397A1
(fr)
*
|
1997-12-24 |
1999-07-08 |
Corixa Corporation |
Composes destines a l'immunotherapie et au diagnostic du cancer du sein, et leur mode d'utilisation
|
US6432707B1
(en)
|
1997-12-24 |
2002-08-13 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of breast cancer
|
US6410507B1
(en)
|
1997-12-24 |
2002-06-25 |
Corixa Corporation |
Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
|
US6379951B1
(en)
|
1997-12-24 |
2002-04-30 |
Corixa Corporation |
Compounds for immunotherapy of breast cancer and methods for their use
|
US6080399A
(en)
*
|
1998-04-23 |
2000-06-27 |
Arch Development Corporation |
Vaccine adjuvants for immunotherapy of melanoma
|
US6534482B1
(en)
*
|
1998-05-13 |
2003-03-18 |
Epimmune, Inc. |
Expression vectors for stimulating an immune response and methods of using the same
|
US7264965B2
(en)
*
|
1998-06-05 |
2007-09-04 |
Alexis Biotech Limited |
Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
|
US7521197B2
(en)
*
|
1998-06-05 |
2009-04-21 |
Alexis Biotech Limited |
Method for producing cytotoxic T-cells
|
US20020051783A1
(en)
*
|
1998-06-05 |
2002-05-02 |
Savage Philip Michael |
Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
|
IL125608A0
(en)
|
1998-07-30 |
1999-03-12 |
Yeda Res & Dev |
Tumor associated antigen peptides and use of same as anti-tumor vaccines
|
AU766278B2
(en)
*
|
1998-09-01 |
2003-10-16 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
PAGE-4, an X-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor
|
US6468758B1
(en)
|
1998-09-23 |
2002-10-22 |
Corixa Corporation |
Compositions and methods for ovarian cancer therapy and diagnosis
|
US20070020327A1
(en)
*
|
1998-11-10 |
2007-01-25 |
John Fikes |
Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
|
CA2334958A1
(fr)
*
|
1998-12-24 |
2000-07-06 |
New York Medical College |
Mimetiques peptidiques utiles pour traiter des maladies
|
IT1309584B1
(it)
*
|
1999-02-26 |
2002-01-24 |
San Raffaele Centro Fond |
Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
|
US6190670B1
(en)
*
|
1999-04-12 |
2001-02-20 |
Immtech International Inc. |
Use of mCRP to enhance immune responses
|
IT1312568B1
(it)
*
|
1999-05-21 |
2002-04-22 |
Genera Spa |
Peptidi immunogenici e loro uso.
|
AU5045900A
(en)
*
|
1999-05-25 |
2000-12-12 |
Beth Israel Deaconess Medical Center |
Meth1 and meth2 polynucleotides and polypeptides
|
DE19925235A1
(de)
|
1999-06-01 |
2000-12-07 |
Medigene Ag |
Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
|
DE19925199A1
(de)
*
|
1999-06-01 |
2000-12-07 |
Medigene Ag |
Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
|
CA2377525A1
(fr)
*
|
1999-07-19 |
2001-03-29 |
Epimmune, Inc. |
Induction de reponses immunitaires cellulaires au virus de l'hepatite c mettant en oeuvre des compositions de peptides et d'acide nucleique
|
WO2001023577A2
(fr)
*
|
1999-09-30 |
2001-04-05 |
Institut Pasteur |
Polynucleotides hybrides ou chimeriques, proteines et compositions comprenant des sequences du virus de l'hepatite b
|
US6897288B1
(en)
*
|
1999-10-19 |
2005-05-24 |
Ludwig Institute For Cancer Research |
Mage-A12 antigenic peptides and uses thereof
|
ATE445643T1
(de)
*
|
1999-11-18 |
2009-10-15 |
Pharmexa Inc |
Heteroklitische analoga von klasse-i epitopen
|
WO2001040269A2
(fr)
|
1999-11-30 |
2001-06-07 |
Corixa Corporation |
Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
|
JP2003517310A
(ja)
*
|
1999-12-10 |
2003-05-27 |
エピミューン, インコーポレイテッド |
ペプチドおよび核酸組成物を使用する、mage2/3に対する細胞性免疫応答の誘導
|
US7026443B1
(en)
*
|
1999-12-10 |
2006-04-11 |
Epimmune Inc. |
Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
|
CA2393662A1
(fr)
*
|
1999-12-10 |
2001-06-14 |
Epimmune Inc. |
Declenchement de reponses immunitaires cellulaires contre p53 au moyen de compositions d'acides nucleiques et de peptides
|
US20070098776A1
(en)
*
|
1999-12-13 |
2007-05-03 |
Fikes John D |
HLA class I A2 tumor associated antigen peptides and vaccine compositions
|
CA2394741A1
(fr)
*
|
1999-12-21 |
2001-06-28 |
Epimmune Inc. |
Induction de reponses immunitaires cellulaires aux antigenes du cancer de la prostate au moyen de compositions de peptides et d'acides nucleiques
|
US20040248113A1
(en)
*
|
1999-12-28 |
2004-12-09 |
Alessandro Sette |
Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
|
US7462354B2
(en)
*
|
1999-12-28 |
2008-12-09 |
Pharmexa Inc. |
Method and system for optimizing minigenes and peptides encoded thereby
|
EP1118860A1
(fr)
*
|
2000-01-21 |
2001-07-25 |
Rijksuniversiteit te Leiden |
Méthodes pour sélectionner et produire des épitopes peptidiques de cellules T ainsi que des vaccines comprenant lesdits épitopes sélectionnés
|
ATE513913T1
(de)
*
|
2000-05-10 |
2011-07-15 |
Sanofi Pasteur Ltd |
Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
|
CN1454082A
(zh)
*
|
2000-09-08 |
2003-11-05 |
艾普免疫公司 |
使用肽和核酸组合物诱导针对乙型肝炎病毒的细胞免疫应答
|
WO2002042325A2
(fr)
|
2000-10-31 |
2002-05-30 |
Zycos Inc. |
Acide nucleique de cyp1b1 et ses procedes d'utilisation
|
US20040121946A9
(en)
*
|
2000-12-11 |
2004-06-24 |
John Fikes |
Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
|
CA2430896A1
(fr)
*
|
2000-12-13 |
2002-06-20 |
Argonex Pharmaceuticals, Inc. |
Peptides associes a la classe i du complexe majeur d'histocompatibilite et utiles dans la prevention et le traitement de la tuberculose
|
PL206976B1
(pl)
*
|
2001-02-20 |
2010-10-29 |
Ortho Mcneil Pharm Inc |
Sposoby wytwarzania zawiesiny CD8⁺ do stosowania w leczeniu podmiotu z rakiem lub czerniakiem, sposób produkcji nie występującej naturalnie komórki i nie występująca naturalnie linia komórkowa
|
US20040071671A1
(en)
*
|
2001-02-20 |
2004-04-15 |
Leturcq Didier J. |
Cell therapy method for the treatment of tumors
|
WO2002080848A2
(fr)
|
2001-04-09 |
2002-10-17 |
Mayo Foundation For Medical Education And Research |
Procedes et matieres pour traiter le cancer
|
WO2002092120A1
(fr)
*
|
2001-05-15 |
2002-11-21 |
Ludwig Institute For Cancer Research |
Peptides structurellement modifies et leurs utilisations
|
US7842480B2
(en)
*
|
2001-05-18 |
2010-11-30 |
Mayo Foundation For Medical Education And Research |
Chimeric antigen-specific t cell-activating polypeptides
|
US20060222656A1
(en)
*
|
2005-04-01 |
2006-10-05 |
University Of Maryland, Baltimore |
MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
|
WO2002097044A2
(fr)
*
|
2001-05-25 |
2002-12-05 |
Thomas Jefferson University |
Formes d'epissage alternatives de proteines servant de base pour modalites therapeutiques multiples
|
US20030049253A1
(en)
*
|
2001-08-08 |
2003-03-13 |
Li Frank Q. |
Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
|
IL145926A0
(en)
|
2001-10-15 |
2002-07-25 |
Mor Research Applic Ltd |
Peptide epitopes of mimotopes useful in immunomodulation
|
WO2003105665A2
(fr)
*
|
2002-06-14 |
2003-12-24 |
Mayo Foundation For Medical Education And Research |
Immunisation specifique par le virus epstein-barr
|
AU2003275127A1
(en)
|
2002-09-19 |
2004-04-08 |
Merial Limited |
P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
|
EP1572968B1
(fr)
|
2002-10-29 |
2009-04-22 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Polypeptides de lutzomyia longipalpis et methodes d'utilisation desdits polypeptides
|
EP1609107A4
(fr)
*
|
2003-03-28 |
2006-08-30 |
Idm Pharma Inc |
Procedes d'identification de variants optimaux d'epitopes peptidiques
|
US20050249743A1
(en)
*
|
2004-01-12 |
2005-11-10 |
Thierry Boon-Falleur |
Isolated peptides which bind to HLA-A24 molecules and uses thereof
|
WO2005115447A2
(fr)
*
|
2004-05-25 |
2005-12-08 |
The Trustees Of The University Of Pennsylvania |
Immunotherapie anticancereuse humaine
|
AU2005250170A1
(en)
*
|
2004-06-01 |
2005-12-15 |
Genimmune N.V. |
Peptides for inducing a CTL and/or HTL response to hepatitis C virus
|
JP5166025B2
(ja)
*
|
2004-06-17 |
2013-03-21 |
マンカインド コーポレイション |
エピトープアナログ
|
DE102004049223A1
(de)
*
|
2004-10-08 |
2006-04-20 |
Johannes-Gutenberg-Universität Mainz |
Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
|
PL1942932T3
(pl)
|
2005-08-08 |
2013-11-29 |
Univ Oregon Health & Science |
Inaktywacja patogenów nadtlenkiem wodoru do wytwarzania szczepionek
|
EP2397852B1
(fr)
|
2006-03-14 |
2013-12-04 |
Oregon Health and Science University |
Procédés pour détecter une infection de tuberculose à mycobactérie
|
US20090220534A1
(en)
*
|
2006-03-16 |
2009-09-03 |
Leiden University Medical Center |
Methods for identifying t-cell epitopes associated with impaired peptide processing and applications of the identified epitopes
|
WO2008053573A1
(fr)
|
2006-10-30 |
2008-05-08 |
National University Corporation Hokkaido University |
Remède pour néoplasme malin
|
EP2125868B1
(fr)
|
2007-02-28 |
2015-06-10 |
The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services |
Polypeptides brachyury et procédés d'utilisation
|
US20090117123A1
(en)
*
|
2007-11-02 |
2009-05-07 |
National Health Research Institutes |
Immunopeptides of hpv e6 and e7 proteins
|
AU2009232774B2
(en)
|
2008-03-31 |
2014-05-29 |
Tella Inc. |
Partial peptide of Survivin presented on MHC class II molecule and use thereof
|
WO2010086294A2
(fr)
|
2009-01-28 |
2010-08-05 |
Epimmune Inc. |
Polypeptides de liaison de pan-dr et leurs utilisations
|
JP2012516350A
(ja)
*
|
2009-01-28 |
2012-07-19 |
アンティジェン・エクスプレス・インコーポレーテッド |
インフルエンザに対する免疫応答を調節するIi−Keyハイブリッドペプチド
|
WO2010099472A2
(fr)
|
2009-02-27 |
2010-09-02 |
The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services |
Polypeptides spanx-b et leur utilisation
|
AU2010305273B2
(en)
|
2009-10-07 |
2016-09-29 |
Uvic Industry Partnerships Inc. |
Vaccines comprising heat-sensitive transgenes
|
EP3360566B1
(fr)
|
2009-11-20 |
2019-12-25 |
Oregon Health&Science University |
Procedes destines a detecter une infection par mycrobacterium tuberculosis
|
WO2011112599A2
(fr)
|
2010-03-12 |
2011-09-15 |
The United States Of America, As Represented By The Secretary. Department Of Health & Human Services |
Peptides pote immunogènes et leurs procédés d'utilisation
|
AU2011302360B2
(en)
|
2010-09-14 |
2015-01-29 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Computationally optimized broadly reactive antigens for influenza
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
KR20140047069A
(ko)
|
2011-06-20 |
2014-04-21 |
유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
계산에 최적화된 광범위 반응을 나타내는 h1n1 인플루엔자를 위한 항원
|
CN107266558A
(zh)
|
2011-09-06 |
2017-10-20 |
诺沃—诺迪斯克有限公司 |
Glp‑1衍生物
|
EP3766896A1
(fr)
|
2011-09-15 |
2021-01-20 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Récepteurs des lymphocytes t reconnaissant un gène mage restreint par hla-a1 ou hla-cw7
|
SG11201404653UA
(en)
|
2012-02-07 |
2014-09-26 |
Univ Pittsburgh |
Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
|
EP2814837B1
(fr)
|
2012-02-13 |
2017-11-29 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Antigènes largement réactifs optimisés par ordinateur pour la grippe h5n1 humaine et aviaire
|
ES2752190T3
(es)
|
2012-09-14 |
2020-04-03 |
Us Health |
Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
|
AU2014361788B2
(en)
|
2013-12-13 |
2019-10-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Multi-epitope TARP peptide vaccine and uses thereof
|
KR101804343B1
(ko)
|
2014-02-26 |
2017-12-04 |
텔라 가부시키가이샤 |
Wt1 항원성 폴리펩티드 및 상기 폴리펩티드를 포함하는 항종양제
|
US10117922B2
(en)
|
2014-05-13 |
2018-11-06 |
Emergex Vaccines Holding Ltd. |
Dengue virus specific multiple HLA binding T cell epitopes for the use of universal vaccine development
|
EP3177320B1
(fr)
|
2014-07-31 |
2021-01-06 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Anticorps monoclonaux humains dirigés contre l'epha4 et leur utilisation
|
CN108289940B
(zh)
|
2015-08-03 |
2023-01-13 |
美国卫生和人力服务部 |
Brachyury缺失突变体、编码brachyury缺失突变体的非酵母载体及其用途
|
CN105037559B
(zh)
*
|
2015-08-17 |
2018-09-25 |
北京康爱瑞浩生物科技股份有限公司 |
治疗或预防乙肝的细胞毒性t淋巴细胞及其制备方法
|
CN109069575A
(zh)
*
|
2016-02-23 |
2018-12-21 |
毛里齐奥·扎内蒂 |
通用癌症疫苗
|
US11141475B2
(en)
|
2016-05-10 |
2021-10-12 |
Najit Technologies, Inc. |
Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
|
US20180161433A1
(en)
*
|
2017-03-22 |
2018-06-14 |
Timothy Andrew Erickson |
Size tunable microbial mimetics for immunotherapy of thyroid carcinomas and solid tumors
|
BR112019023477A2
(pt)
|
2017-05-08 |
2020-06-30 |
Gritstone Oncology, Inc. |
vetores de neoantígeno de alfavírus
|
WO2019133853A1
(fr)
*
|
2017-12-28 |
2019-07-04 |
Gritstone Oncology, Inc. |
Protéines se liant à l'antigène ciblant des antigènes partagés
|
KR20200118029A
(ko)
|
2018-01-04 |
2020-10-14 |
아이코닉 테라퓨틱스, 인코포레이티드 |
항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
|
US11344614B2
(en)
|
2018-09-29 |
2022-05-31 |
Emergex Vaccines Holding Ltd. |
Pharmaceutical compositions comprising dengue virus-specific multiple HLA-binding T cell epitopes
|
MX2021014525A
(es)
|
2019-05-30 |
2022-03-17 |
Gritstone Bio Inc |
Adenovirus modificados.
|
AU2020284136A1
(en)
|
2019-05-30 |
2022-01-20 |
Oregon Health & Science University |
Methods for detecting a mycobacterium tuberculosis infection
|
AU2020351168A1
(en)
|
2019-09-18 |
2022-04-14 |
Children's Medical Center Corporation |
An anaplastic lymphoma kinase (ALK) cancer vaccine and methods of use
|
KR20230046313A
(ko)
|
2020-08-06 |
2023-04-05 |
그릿스톤 바이오, 인코포레이티드 |
다중에피토프 백신 카세트
|
FR3119325B1
(fr)
|
2021-01-29 |
2023-08-11 |
Renault Jean Yves |
Compositions liposomales orales
|